Iatrogenic risk factors and correction of dyslipidemia after liver transplantation
- Authors: Kosmacheva E.D1,2, Babich A.E2
-
Affiliations:
- Kuban State Medical University, Ministry of Health of the Russian Federation
- The Research Institute-Regional Clinical Hospital №1 named after Prof. S.V.Ochapovsky of the Ministry of Health of the Krasnodar Region
- Issue: Vol 17, No 1 (2015)
- Pages: 68-71
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94250
- ID: 94250
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E. D Kosmacheva
Kuban State Medical University, Ministry of Health of the Russian Federation; The Research Institute-Regional Clinical Hospital №1 named after Prof. S.V.Ochapovsky of the Ministry of Health of the Krasnodar Regionд-р мед. наук, проф., зав. каф. терапии №1 фак-та повышения квалификации и профессиональной переподготовки специалистов ГБОУ ВПО КубГМУ, зам. глав. врача по мед. части ГБУЗ НИИ-ККБ №1 им. проф. С.В.Очаповского, глав. кардиолог Южного федерального округа и Краснодарского края 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4
A. E Babich
The Research Institute-Regional Clinical Hospital №1 named after Prof. S.V.Ochapovsky of the Ministry of Health of the Krasnodar Region
Email: Anna-babich1@yandex.ru
врач-терапевт хирургического отд-ния №1 ГБУЗ НИИ-ККБ №1 им. проф. С.В.Очаповского 350029, Russian Federation, Krasnodar, ul. 1 Maia, d. 16
References
- Национальные рекомендации по кардиоваскулярной профилактике. 1-е изд. 2011. Кардиоваск. терапия и профилактика. 2011; 10 (6; Прил. 2).
- Gisbert C, Prieto M, Berenguer M et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997; 3 (4): 416-22.
- Bianchi G, Marchesini G, Marzocchi R et al. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14 (11): 1648-54.
- Guckelberger O, Bechstein W.O, Neuhaus R et al. Cardiovascular risk factors in long - term follow - up after orthotopic liver transplantation. Clin Transpl 1997; 11 (1): 60-5.
- Laryea M, Watt K.D, Molinari M et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13 (8): 1109-14.
- Muñoz L.E, Nañez H, Rositas F et al. Long - term complications and survival of patients after orthotopic liver transplantation. Transplant Proc 2010; 42 (6): 2381-2.
- Muñoz S.J, El Genaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005; 11 (Suppl. 2): S52-S56.
- Kobashigawa J.A, Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331-8.
- Imagawa D.K, Dawson S, 3rd, Holt C.D et al. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxyl - methylglutaryl - coenzyme A reductase inhibitor pravastatin. Transplantation 1996; 62: 934-42.
- Munoz S.J, Deems R.O, Moritz M.J et al. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc 1991; 23: 1480-3.
- Lucey M.R, Terrault N, Ojo L et al. Long Term Management of the Successful Adult Liver Transplant: 2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3-26.
- Bianchi G, Marchesini G, Marzocchi R et al. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14 (11): 1648-54.
- Neal D.A, Tom B.D, Luan J. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004; 77 (1): 93-9.
- Johnston S.D, Morris J.K, Cramb R et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73 (6): 901-6.
- Ciccarelli O, Kaczmarek B, Roggen F. Long - term medical complications and quality of life in adult recipients surviving 10 years or more after liver transplantation. Acta Gastroenterol Belg 2005; 68 (3): 323-30.
- Watt K.D, Pedersen R.A, Kremers W.K et al. Evolution of causes and risk factors for mortality post - liver transplant: results of the NIDDK long - term follow - up study. Am J Transpl 2010; 10 (6): 1420-7.
- Neal D.A, Gimson A.E, Gibbs P, Alexander G.J. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001; 7 (6): 533-9.
- Clark W. Tacrolimus: immunosuppression following liver and kidney transplant. J Clin Pharm Ther 1996; 21: 135-41.
- Guckelberger O, Bechstein W.O, Neuhaus R et al. Cardiovascular risk factors in long - term follow - up after orthotopic liver transplantation. Clin Transplant 1997; 11: 60-5.
- Rabkin J.M, Corless C.L, Rosen H.R, Olyaei A.J. Immunosuppression impact on long - term cardiovascular complications after liver transplantation. Am J Surg 2002; 183: 595-9.
- Stegall M.D, Wachs M.E, Everson G et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 1755-60.
- Manzarbeitia C, Reich D.J, Rothstein K.D et al. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl 2001; 7: 93-9.
- Morard I, Dumortier J, Spahr L. Conversion to sirolimus - based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007; 13 (5): 658-64.
- Stegall M.D, Everson G.T, Schroter G et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 1997; 25: 173-7.
- Boillot O, Mayer D.A, Boudjema K et al. Corticosteroid - free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 11: 61-7.
- Segev D.L, Sozio S.M, Shin E.J et al. Steroid avoidance in liver transplantation: meta - analysis and meta - regression of randomized trials. Liver Transpl 2008; 14: 512-25.
- Moench C, Barreiros A.P, Schuchmann M et al. Tacrolimus monotherapy without steroids after liver transplantation - a prospective randomized double - blinded placebo - controlled trial. Am J Transpl 2007; 7: 1616-23.
- Siddharth Singh, Watt K.D. Long - term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc 2012; 87 (8): 779-90.
- Космачева Е.Д., Бабич А.Э. Особенности ведения пациентов с артериальной гипертензией после трансплантации печени. Системные гипертензии. 2014; 4: 55-7.
- Pokrovskii V.M, Kompaniets O.G. Influence of the level of blood pressure on the regulatory - adaptive state. Hum Physiol 2012; 38 (5): 539-42.
- Покровский В.М., Компаниец О.Г. Регуляторно - адаптивный статус пациентов с гипертонической болезнью при медикаментозном достижении целевых уровней артериального давления. Системные гипертензии. 2011; 2: 58-60.
- Ратова Л.Г., Чазова И.Е. Эффективность и безопасность лечения β - адреноблокатором III поколения пациентов с артериальной гипертонией. Consilium Medicum. 2009; 5.
- Компаниец О.Г., Аверин Е.Е. Приоритеты выбора диуретиков при лечении гипертонической болезни: доказательная медицина, рекомендательные документы и реальная клиническая практика. Системные гипертензии. 2013; 1: 62-5.
- Карташева Е.Д., Линчак Р.М. Роль β - адреноблокаторов в лечении и профилактике сердечно - сосудистых заболеваний: акцент на карведилол. Трудный пациент. 2010; 8 (5): 21-7.
- Пономарева А.И., Одноволов О.Т., Компаниец О.Г., Чернявская Д.Е. Комбинированная фармакотерапия артериальной гипертензии. Consilium Medicum. 2013; 1: 11-4.
- International Atherosclerosis Society, IAS. Меморандум Международного общества по изучению атеросклероза: Общие рекомендации по лечению дислипидемии. 2014; с. 1-67. http://scardio.ru/content/Guidelines/IAS/PositionPaperRussianlanguage.pdf США / International Atherosclerosis Society, IAS. Memorandum Mezhdunarodnogo obshchestva po izucheniiu ateroskleroza: Obshchie rekomendatsii po lecheniiu dislipidemii. 2014; s. 1-67. http://scardio.ru/content/Guidelines/IAS/PositionPaper-Russianlanguage.pdf SShA [in Russian]
- Martin J.E, Cavanaugh T.M, Trumbull L. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transpl 2008; 22 (1): 113-9.
- Asberg A. Interactions between cyclosporin and lipid - lowering drugs: implications for organ transplant recipients. Drugs 2003; 63 (4): 367-78.
- Общероссийская общественная организация трансплантологов «Российское трансплантологическое общество». Трансплантация печени. Национальные клинические рекомендации 2013. http://transpl.ru/images/cms/data/pdf/nacional_nye_klinicheskie_rekomendacii_po_transplantacii_pecheni.pdf
- Государственный реестр лекарственных средств. http://grls.rosminzdrav.ru
- Mc Kenney J.M, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm 2007; 64 (6): 595-605.
- Lee S, Gura K.M, Puder M. Omega-3 fatty acids and liver disease. Hepatology 2007; 45 (4): 841-5.
- Almutairi F, Peterson T.C, Molinari M. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl 2009; 15 (5): 504-8.